Document is current

Article History

Received: 22 April 2021

Accepted: 28 June 2021

First Online: 24 July 2021

Declarations

:

: The local Ethics Committee on Animal Experimentation of the State University of Maringá approved the experimental procedures in accordance with the guidelines of the U.S. National Institutes of Health and Brazilian College for Animal Experimentation (animal license number: CEUA 1555230316).

: This study was carried out at the State University of Maringá in strict accordance with the Brazilian College of Animal Experimentation (COBEA) recommendations. Animal experiments were approved by the local Ethics Committee on Animal Experimentation of the State University of Maringá (animal license number: CEUA 1555230316).

: All of the co-authors approved the final version of the manuscript and agreed to submit it to Molecular Neurobiology.

: FSG is a co-inventor (Mechoulam R, JC, Guimaraes FS, AZ, JH, Breuer A) of the patent “Fluorinated CBD compounds, compositions, and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US No. Reg. 62193296; 29/07/2015; INPI on 19/08/2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders.”